arrow
M

Monique C. Minnema

University Medical Center Utrecht
H指数:59
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple myeloma in the Netherlands: 35-year trends in incidence and survival

荷兰多发性骨髓瘤:35年发病率和生存趋势

Leukemia
IF13.4
2026-10-220
OAAI
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

EMN12/HOVON-129研究移植适宜队列中初发浆细胞白血病患者长期随访

2026-06-240
OAAI
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Daratumumab-硼替佐米-环磷酰胺-地塞米松治疗新诊断的淀粉样变性: 仙女座最终生存分析

Blood
IF23.1
2026-05-140
OAAI
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

奥加曲沙在瓦尔登斯特伦巨球蛋白血症中,5年随访显示持久应答

2026-04-170
OAAI
Author Correction: Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

作者更正:通过凋亡调控增强骨髓瘤杀伤效果的BCMA CAR T细胞工程

2026-04-130
OAAI
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma

BCMA靶向双特异性T细胞接合剂pavurutamab在复发/难治性多发性骨髓瘤中的1/1b期研究

Blood
IF23.1
2026-04-090
PRE
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial

FDG-PET骨髓总肿瘤体积在CASSIOPEIA试验中凸显高风险新诊断多发性骨髓瘤患者

2026-03-310
OAAI
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma

泽鲁布替尼在与华氏巨球蛋白血症及其他B细胞非霍奇金淋巴瘤相关的AL淀粉样变性中的应用

2026-03-160
OAAI
DIAGNOSING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA THROUGH MODERN MARKERS IN CEREBROSPINAL FLUID: A MULTICENTER PROSPECTIVE COHORT STUDY (PRICELUS)

通过现代标志物在脑脊液中诊断原发性中枢神经系统淋巴瘤:一项多中心前瞻性队列研究(PRICELUS)

2025-11-010
PRE
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

CASSIOPEIA试验中,新诊断多发性骨髓瘤患者维持治疗前的FDG PET/CT反应的预后价值

Blood
IF23.1
2025-09-260
PRE
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia

第十二届瓦尔登斯特罗姆巨球蛋白血症患者 Bing-Neel 综合症管理国际研讨会共识小组 2 的报告

2025-04-160
PRE
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors

第十二届华氏巨球蛋白血症国际研讨会第五共识小组关于对共价BTK抑制剂不耐受或耐药患者管理的报告

2025-04-080
PREAI
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

接受brexucabtagene autoleucel治疗的复发或难治性B细胞急性淋巴细胞白血病成年患者的三年分析(ZUMA-3)

LEUKEMIA
IF13.4
2025-03-191
OAAI
Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

扩展尤里卡研究:整合综合临床登记与分子图谱以推进AL淀粉样变性研究

BLOOD
IF23.1
2024-11-050
PRE